Chugai Pharmaceutical of Japan has signed a research and licensing agreement with AI-focused biotech Gero PTE of Singapore to develop therapies targeting age-related diseases. The partnership combines Gero’s AI-driven target discovery technology with Chugai’s antibody engineering expertise, aiming to accelerate innovation aligned with Chugai’s TOP I 2030 growth strategy. The agreement includes up to $250 million in development and sales milestones, royalties on sales, and global rights for antibody therapeutics created from Gero’s identified targets. This collaboration exemplifies a continued trend of integrating AI platforms into drug discovery for complex conditions like aging.